1. |
Dolecek T A, Propp J M, Stroup N E, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol, 2012, 14(Suppl 5): v1-v49.
|
2. |
Klemm F, Joyce J A. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol, 2015, 25(4): 198-213.
|
3. |
Kumar V, Patel S, Tcyganov E, et al. The Nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol, 2016, 37(3): 208-220.
|
4. |
Gieryng A, Pszczolkowska D, Walentynowicz K A, et al. Immune microenvironment of gliomas. Laboratory Investigation, 2017, 97(5): 498-518.
|
5. |
Mieczkowski J, Kocyk M, Nauman P, et al. Down-regulation of IKKβ expression in glioma-infltrating microglia/macrophages is associated with defective in?ammatory/immune gene responses in glioblastoma. Oncotarget, 2015, 6(32): 33077-33090.
|
6. |
Szulzewsky F, Arora S, de Witte L, et al. Human glioblastoma-associated microglia/monocytes express a distinct RNA profle compared to human control and murine samples. Glia, 2016, 64(8): 1416-1436.
|
7. |
Pyonteck S M, Akkari L, Schuhmacher A J, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med, 2013, 19(10): 1264-1272.
|
8. |
Zhao Aimin, Xu Haijing, Kang Xiaomin, et al. New insights into myeloid-derived suppressor cells and their roles in feto-maternal immune cross-talk. J Reprod Immunol, 2016, 113: 35-41.
|
9. |
Gielen P R, Schulte B M, Kers-Rebel E D, et al. Increase in both CD14-Positive and CD15-Positive Myeloid-Derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-Positive myeloid-derived suppressor cells in glioma tissue. J Neuropathol Exp Neurol, 2015, 74(5): 390-400.
|
10. |
Gielen P R, Schulte B M, Kers-Rebel E D, et al. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly Express S100A8/9 and arginase and suppress T cell function. Neuro Oncol, 2016, 18(9): 1253-1264.
|
11. |
Abad C, Nobuta H, LI J, et al. Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma. J Leukoc Biol, 2014, 95(2): 357-367.
|
12. |
Mao Yumeng, Poschke I, Wennerberg E, et al. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res, 2013, 73(13): 3877-3887.
|
13. |
Cheng P, Corzo C A, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med, 2008, 205(10): 2235-2249.
|
14. |
Heimberger A B, Abou-Ghazal M, Reina-Ortiz C A, et al. Incidence and prognostic impact of FoxP3(+) regulatory T cells in human gliomas. Clinical Cancer Research, 2008, 14(16): 5166-5172.
|
15. |
Maes W, Verschuere T, van Hoylandt A, et al. Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain. Clin Dev Immunol, 2013, 2013: 952469.
|
16. |
Sampson J H, Schmittling R J, Archer G E, et al. A pilot study of IL-2R alpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One, 2012, 7(2): e31046.
|
17. |
Kmiecik J, Poli A, Brons N H, et al. Elevated CD3(+) and CD8(+) tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol, 2013, 264(1/2): 71-83.
|
18. |
Mu Luyan, Yang Changlin, Gao Qiang, et al. CD4+and perivascular Foxp3+ T cells in glioma correlate with angiogenesis and tumor progression. Front Immunol, 2017, 8: 1451.
|
19. |
Baker G J, Chockley P, Zamler D, et al. Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells. Oncoimmunology, 2016, 5(6): e1163461.
|
20. |
Chang A L, Miska J, Wainwright D A, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res, 2016, 76(19): 5671-5682.
|
21. |
Kjellman C, Olofsson S P, Hansson O, et al. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer, 2000, 89(3): 251-258.
|
22. |
Qi Ling, Yu Hongquan, Zhang Yu, et al. IL-10 secreted by M2 macrophage promoted tumorigenesis through interaction with JAK2 in glioma. Oncotarget, 2016, 7(44): 71673-71685.
|
23. |
Rodrigues J C, Gonzalez G C, Zhang L, et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol, 2010, 12(4): 351-365.
|
24. |
Cantini G, Pisati F, Mastropietro A A, et al. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. Cancer Immunology Immunotherapy, 2011, 60(12): 1739-1750.
|
25. |
Otvos B, Silver D J, Mulkearns-Hubert E E, et al. Cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glioblastoma immune evasion. Stem Cells, 2016, 34(8): 2026-2039.
|
26. |
Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res, 2003, 63(21): 7462-7467.
|
27. |
Kohanbash G, Mckaveney K, Sakaki M, et al. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-alpha. Cancer Res, 2013, 73(21): 6413-6423.
|
28. |
Pillay J, Tak T, Kamp V M, et al. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cellular and Molecular Life Sciences, 2013, 70(20): 3813-3827.
|
29. |
Leroi N, Lallemand F, Coucke P, et al. Impacts of ionizing radiation on the different compartments of the tumor microenvironment. Front Pharmacol, 2016, 7: 78.
|
30. |
Bronte V, Brandau S, Chen S H, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun, 2016, 7: 12150.
|
31. |
Youn J I, Gabrilovich D I. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol, 2010, 40(11): 2969-2975.
|
32. |
Kumar R, de Mooij T, Peterson T, et al. Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane. Neuro Oncol, 2016, 18(6): 99-100.
|
33. |
Raychaudhuri B, Rayman P, Ireland J, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol, 2011, 13(6): 591-599.
|
34. |
Dubinski D, Wölfer J, Hasselblatt M, et al. CD4+T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro Oncol, 2016, 18(6): 807-818.
|
35. |
Raychaudhuri B, Rayman P, Huang P A, et al. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J Neurooncol, 2015, 122(2): 293-301.
|
36. |
Chae M, Peterson T E, Balgeman A, et al. Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. Neuro Oncol, 2015, 17(7): 978-991.
|
37. |
Fujita M, Kohanbash G, Fellows-Mayle W, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res, 2011, 71(7): 2664-2674.
|
38. |
Verschuere T, Toelen J, Maes W, et al. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. International Journal of Cancer, 2014, 134(4): 873-884.
|
39. |
Zhang Y, Luo F, Li A, et al. Systemic injection of TLR1/2 agonist improves adoptive antigen-specific T cell therapy in glioma-bearing mice. Clin Immunol, 2014, 154(1): 26-36.
|
40. |
Zhu Xinmei, Fujita M, Snyder L A, et al. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol, 2011, 104(1): 83-92.
|
41. |
Kamran N, Kadiyala P, Saxena M, et al. Immunosuppressive myeloid cells' blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy. Mol Ther, 2017, 25(1): 232-248.
|